Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.81 |
| ▸ | LCK | P06239 | 10/20 | 0.81 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.81 |
| ▸ | MAP4K2 | Q12851 | 9/20 | 0.81 |
| ▸ | CLK2 | P49760 | 8/20 | 0.81 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.81 |
| ▸ | AXL | P30530 | 8/20 | 0.81 |
| ▸ | BLK | P51451 | 8/20 | 0.81 |
| ▸ | STK3 | Q13188 | 8/20 | 0.81 |
| ▸ | SLK | Q9H2G2 | 8/20 | 0.81 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.81 |
| ▸ | FLT3 | P36888 | 8/20 | 0.81 |
| ▸ | LIMK1 | P53667 | 7/20 | 0.81 |
| ▸ | CSNK1G2 | P78368 | 7/20 | 0.81 |
| ▸ | CAMK2G | Q13555 | 7/20 | 0.81 |
| ▸ | CAMK2D | Q13557 | 7/20 | 0.81 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.81 |
| ▸ | TAOK1 | Q7L7X3 | 7/20 | 0.81 |
| ▸ | PLK4 | O00444 | 7/20 | 0.81 |
| ▸ | MARK3 | P27448 | 7/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486611 | 0.89 | KDR (1.00) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4477423 | 0.89 | KDR (0.78) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4471506 | 0.85 | KDR (0.83) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4478720 | 0.85 | KDR (0.76) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4472667 | 0.84 | KIT (1.00) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4761640 | 0.84 | PLK4 (0.81) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4474877 | 0.84 | KDR (0.80) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4477648 | 0.83 | KDR (1.00) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL232042 | 0.83 | KDR (1.00) | KDRLCKMAP4K4MAP4K2CLK2 | |
| SCHEMBL4478814 | 0.83 | KDR (0.78) | KDRLCKMAP4K4MAP4K2CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885LCK 3/4885MAP4K4 108/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KDR 391/4885LCK 2/4885MAP4K4 127/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KDR 425/4885LCK 3/4885MAP4K4 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.